Abstract 1781P
Background
In ARAMIS (NCT02200614), DARO plus androgen-deprivation therapy (ADT) significantly increased metastasis-free survival by nearly 2 years and reduced the risk of death by 31% in patients (pts) with nmCRPC. DARO also significantly delayed time to deterioration of HRQoL and had a positive impact on local disease recurrence and symptom control. We report the effect of DARO on HRQoL DetFS by PSA decline in ARAMIS.
Methods
Pts with nmCRPC were randomized 2:1 to DARO or placebo, both with ADT. Using the primary analysis data cutoff (Sept 3, 2018), DARO-treated pts were grouped by PSA decline from baseline at wk 16 of ≥90% (PSA90), ≥50% to <90% (PSA50-90), and <50% (PSA50). DetFS was defined as the time from randomization until the earliest event of deterioration in HRQoL (EORTC Quality of Life Questionnaire Prostate Cancer Module urinary and bowel symptoms subscales and Functional Assessment of Cancer Therapy-Prostate [FACT-P] prostate cancer subscale [PCS] and Total), metastasis, death, or treatment discontinuation. Median (95% CIs) DetFS was calculated using Kaplan-Meier estimates.
Results
Of 955 DARO pts, 899 had PSA values at wk 16 and 403 (44.8%) achieved PSA90. Pts achieving PSA90 decline had longer median DetFS of HRQoL for urinary and bowel symptoms and for FACT-P Total and PCS vs those with PSA50-90 and <50% PSA decline (Table). For pts with PSA90, PSA50-90, and <50% PSA decline, 3-year DetFS rates were 38.0%, 31.2%, and 14.6% for urinary symptoms and 33.8%, 17.4%, and 13.3% for bowel symptoms.
Table: 1781P
HRQoL DetFS in DARO-treated pts by PSA decline from baseline at wk 16
DetFS, median (95% CI), months | PSA ≥90% decline (n=403) | PSA ≥50% to <90% decline (n=379) | PSA <50% decline (n=117) |
EORTC urinary symptoms subscale | 22.3 (18.6–30.8) | 18.5 (14.8–22.2) | 11.6 (7.6–15.0) |
EORTC bowel symptoms subscale | 25.6 (18.4–26.0) | 14.7 (11.2–15.0) | 11.5 (7.6–15.0) |
FACT-P PCS | 22.3 (18.4–NR) | 15.0 (11.1–18.5) | 11.1 (7.6–18.3) |
FACT-P Total | NR (NR–NR) | 32.9 (26.0–40.5) | 16.1 (11.1–25.8) |
NR, not reached.
Conclusions
In ARAMIS, a high proportion of DARO pts achieved PSA90. DARO demonstrated local symptom control for urinary and bowel measures and better HRQoL in pts who achieved PSA90. These findings confirm the cancer control and HRQoL benefits of early DARO treatment for pts with nmCRPC.
Clinical trial identification
NCT02200614.
Editorial acknowledgement
Medical writing support was provided by Michelle McDermott, of OPEN Health Communications (London, UK).
Legal entity responsible for the study
Bayer AG and Orion Pharma.
Funding
Bayer AG and Orion Pharma.
Disclosure
A.K. Morgans: Financial Interests, Personal, Other, Honoraria: Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Clovis, Exelixis, Genentech, Janssen, Merck, Myovant, Pfizer, Sanofi, Telix; Financial Interests, Personal, Other, travel support: Sanofi; Financial Interests, Institutional, Research Funding: Astellas, AstraZeneca, Bayer, Genentech, Myovant, Sanofi, Seattle Genetics. C. Sweeney: Financial Interests, Personal, Advisory Board, Consultancy: Genentech_Roche, Bayer, Astellas, Pfizer, Pfizer, Sanofi, Lilly; Financial Interests, Personal, Other, Consultancy: Janssen; Financial Interests, Personal, Advisory Board: Point, Cellcentric; Financial Interests, Personal, Stocks/Shares: Leuchemix; Financial Interests, Institutional, Research Grant: Bayer, Janssen, Astellas, Pfizer, Dendreon, Sanofi. C. Wallis: Financial Interests, Personal, Other, Honoraria: Bayer, EMD Serono, Knight Therapeutics, Haymarket Media, Science & Medicine Canada, TerSera Canada, Tolmar Pharmaceuticals Canada; Financial Interests, Personal, Speaker, Consultant, Advisor: Janssen Oncology, SESEN Bio, Precision Point Specialty LLC; Financial Interests, Institutional, Research Funding: Knight Therapeutics. S. Halabi: Financial Interests, Personal, Other, Member of DSMB: Sanofi, Aveo Oncology, BMS, Janssen; Financial Interests, Institutional, Funding: ASCO. A.J. Armstrong: Financial Interests, Personal, Advisory Role: Bayer, Pfizer, Astellas Scientific and Medical Affairs Inc, AstraZeneca, Merck, BMS, Janssen, FORMA Therapeutics, Novartis, Exelixis, Myovant Sciences, GoodRx, Epic Sciences, IDEAYA Biosciences; Financial Interests, Personal, Other, travel, accommodations, expenses: Astellas Scientific and Medical Affairs Inc; Financial Interests, Personal, Licencing Fees or royalty for IP: Circulating tumor cell novel capture technologies; Financial Interests, Institutional, Research Funding: Dendreon, Bayer, Pfizer, Novartis, Janssen Oncology, Astellas Pharma, Gilead Sciences, Roche/Genentech, BMS, Constellation Pharmaceuticals, Merck, AstraZeneca, BeiGene, Amgen, FORMA Therapeutics. P. Adorjan: Financial Interests, Personal, Full or part-time Employment: Bayer; Financial Interests, Personal, Stocks or ownership: Biogen. A.F. Mohamed, F. Verholen, S. Srinivasan: Financial Interests, Personal, Full or part-time Employment: Bayer. M. Grimm: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Ipsen Pharma, Merck Serono, MSD, Pfizer, EUSA, Janssen, Oncinfo; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, BMS, EUSA Pharma, Ipsen Pharma, Merck Serono, MSD, Pfizer, Roche, Eisai, Takeda, Janssen Cilag, Gilead, Novartis; Financial Interests, Personal, Member of Board of Directors: Deutsche Gesellschaft für Urologie; Financial Interests, Personal and Institutional, Coordinating PI: BMS; Financial Interests, Institutional, Local PI: Intuitive Surgical; Financial Interests, Institutional, Coordinating PI: Bayer.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14